Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19304421 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KCNH2ECE1KDM4ENOS1 | |
| Hydrochloric Acid SCHEMBL15526208 | 0.98 | ALDH1A1 (0.41) | ALDH1A1KCNH2ECE1KDM4ENOS1 | |
| SCHEMBL11570650 | 0.92 | SLC6A3 (0.42) | ALDH1A1ECE1NOS1SMN1; SMN2SLC6A3 | |
| SCHEMBL129530 | 0.84 | — | — | |
| SCHEMBL9804172 | 0.83 | NOS1 (0.36) | NOS1SMN1; SMN2 | |
| SCHEMBL7436046 | 0.83 | NOS1 (0.36) | ECE1NOS1SMN1; SMN2 | |
| SCHEMBL6235049 | 0.81 | KCNH2 (0.50) | ALDH1A1KCNH2ECE1KDM4ESLC6A3 | |
| SCHEMBL3578329 | 0.79 | KDM4E (0.48) | ALDH1A1KCNH2ECE1KDM4ESMN1; SMN2 | |
| SCHEMBL31317623 | 0.79 | SLC6A3 (0.46) | ALDH1A1KCNH2ECE1KDM4ESLC6A3 | |
| SCHEMBL28578070 | 0.79 | SLC6A3 (0.46) | ALDH1A1KCNH2ECE1KDM4ESLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| EP-1742909-A4 | ANIONIC-SWEETENER-BASED IONIC LIQUIDS AND METHODS OF USE THEREOF | UNIV SOUTH ALABAMA (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1742909-A2 | ANIONIC-SWEETENER-BASED IONIC LIQUIDS AND METHODS OF USE THEREOF | University Of South Alabama (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005072376-A2 | ANIONIC-SWEETENER-BASED IONIC LIQUIDS AND METHODS OF USE THEREOF | UNIVERSITY OF SOUTH ALABAMA (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | ALDH1A1 1457/4885KCNH2 2308/4885ECE1 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.